1 out of 2 heart attack patients still develops microvascular obstruction (MVO), blockage in the heart’s smallest blood vessels — even after timely treatment. MVO remains a major driver of poor recovery, heart failure, and long-term mortality after heart attack treatment.
A first-in-class dual-action catheter solution, preclinically validated and designed to enhance PCI performance through ultrafast acoustic thrombus disruption, local fragment capture, and closed-loop safety control, without lytic drugs.
Breakthrough research originating at ETH Zurich
Proprietary, patent-pending catheter technology
Compatible with existing PCI workflows
Years of Research
Patents & Pending patent
